A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Sarantopoulos, MD
The University of Texas Health Science Center at San Antonio
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- University Hospital of Cleveland
Cleveland, Ohio, United States
- Ctrc at the University of Texas Healh Science Center at San Antonio
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2013
- Primary completion
- 31 May 2019
- Completion
- 30 Jun 2019
- Last update posted
- 10 Dec 2020
- Registered enrollment
- 83
- Registry id
- NCT01905228
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.